Deferiprone
Based on 48 publication(s) in Google Scholar
Deferiprone is a potent, orally active, brain-penetrant, cell-penetrant, skin-permeable, free iron chelating agent. Deferiprone inhibits the proliferation and migration, and stimulates apoptosis in tumor cell. Deferiprone can inhibit KDM. Deferiprone has antianemic, neuroprotective, anti-inflammatory, antioxidant, and antidotal activity. Deferiprone can be used in cancer, cardiovascular disease, infection, inflammation, and neurological disease study.
For research use only. We do not sell to patients.
- Purity: 99.98%
- CAS No.: 30652-11-0
- Formula: C7H9NO2
- Molecular Weight:139.15
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Apoptosis Compound Library
HY-L003
-
Epigenetics Compound Library
HY-L005
-
Immunology/Inflammation Compound Library
HY-L007
-
FDA-Approved Drug Library
HY-L022
-
Histone Modification Research Compound Library
HY-L024
-
Anti-Cancer Compound Library
HY-L025
-
Antiviral Compound Library
HY-L027
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Antioxidant Compound Library
HY-L037
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Ferroptosis Compound Library
HY-L051
-
Anti-COVID-19 Compound Library
HY-L052
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Alzheimer's Disease Compound Library
HY-L069
-
Neuroprotective Compound Library
HY-L070
-
Anti-Hepatitis C Virus Compound Library
HY-L073
-
Drug-Induced Liver Injury (DILI) Compound Library
HY-L076
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Rare Diseases Drug Library
HY-L102
-
Pediatric Drug Library
HY-L104
-
EMA-Approved Drug Library
HY-L116
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Withdrawn Drug Compound Library
HY-L140
-
Off-patent Drug Library
HY-L141
-
Cell Death Library
HY-L162
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
Cell Death Inhibitor Library Mini
HY-L162M
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
Structurally Diverse Fragment Library
HY-L187
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
Methylation Compound Library
HY-L203
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Drug Fragment Library
HY-L904
Publications Citing Use of MedChemExpress (MCE) Deferiprone
More- Nat Nanotechnol. 2021 Oct;16(10):1150-1160. [Abstract]
- Cell Metab. 2026 Jan 27:S1550-4131(25)00586-8. [Abstract]
- Autophagy. 2025 Oct 13:1-13. [Abstract]
- Autophagy. 2022 Apr 26:1-17. [Abstract]
- Autophagy. 2020 Aug;16(8):1366-1379. [Abstract]
- Adv Sci (Weinh). 2025 Aug 7:e09208. [Abstract]
- J Adv Res. 2024 Aug:62:257-272. [Abstract]
- Biomaterials. 2023 Jan:292:121936. [Abstract]
- Sci Adv. 2023 Nov 15;9(46):eadf4345. [Abstract]
- Redox Biol. 2024 May 13:73:103190. [Abstract]
- Redox Biol. 2024 May 8:73:103182. [Abstract]
- Redox Biol. 2023 Nov:67:102871. [Abstract]
- Redox Biol. 2023 Jul:63:102751. [Abstract]
- Redox Biol. 2020 Jan;29:101402. [Abstract]
- J Hazard Mater. 2021 May 15;410:124566. [Abstract]
- MedComm. 2024 Jan 30;5(2):e473. [Abstract]
- Mol Biomed. 2025 Oct 2;6(1):75. [Abstract]
- Food Chem. 2023 May 15:408:135249. [Abstract]
- Environ Int. 2025 Mar:197:109361. [Abstract]
- J Colloid Interface Sci. 2024 Aug:667:91-100. [Abstract]
- Acta Biomater. 2022 Jun;145:210-221. [Abstract]
- Nano Res. 2023 Apr 18.
- Cell Commun Signal. 2024 Jul 11;22(1):359. [Abstract]
- Phytomedicine. 2021 Jan;80:153370. [Abstract]
- Free Radic Biol Med. 2025 Feb 16:228:93-107. [Abstract]
- Free Radic Biol Med. 2024 May 1:217:1-14. [Abstract]
- Free Radic Biol Med. 2020 Nov 20;160:303-318. [Abstract]
- Chemosphere. 2021 Feb;264(Pt 1):128413. [Abstract]
- Sci Total Environ. 2023 Sep 20:892:164472. [Abstract]
- Sci Total Environ. 2023 Sep 10:890:164172. [Abstract]
- Biomed Pharmacother. 2020 Feb;122:109690. [Abstract]
- Cell Rep. 2023 Dec 6;42(12):113544. [Abstract]
- Cell Biosci. 2026 Apr 26. [Abstract]
- EMBO Rep. 2019 Jul;20(7):e47563. [Abstract]
- Int J Mol Med. 2024 Dec;54(6):110. [Abstract]
- Chin Med. 2025 Jun 16;20(1):89. [Abstract]
- Biochem Pharmacol. 2021 Nov:193:114813. [Abstract]
- Mol Cell Proteomics. 2023 Dec;22(12):100672. [Abstract]
- Eur J Pharmacol. 2024 Mar 5:966:176340. [Abstract]
- Mol Med Rep. 2025 Jul;32(1):202. [Abstract]
- PLoS Negl Trop Dis. 2023 Aug 31;17(8):e0011607. [Abstract]
- Toxicol Appl Pharmacol. 2020 Nov 15;407:115241. [Abstract]
- Metallomics. 2024 Oct 4;16(10):mfae044. [Abstract]
- Mitochondrial Commun. 2024:2:14-20. [Abstract]
- SSRN. 15 Oct 2022.
- Oxid Med Cell Longev. 2022 Apr 25;2022:3846217. [Abstract]
- Research Square Preprint. 2021 Jan.
- Research Square Preprint. 2020 Oct.
Customer Validation & Images
-
Cell Imaging/Staining
-
RT-PCR
-
IF
-
Flow Cytometry
-
WB
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A-375 | IC50 |
27.24 μM
Compound: DFP
|
Cytotoxicity against human A-375 cells assessed as reduction in cell viability preincubated for 4 hrs under dark condition in presence of 5-aminolevulinic acid followed by irradiation with blue light at 2.5 J.cm^-2 energy level for 5 mins and measured aft
Cytotoxicity against human A-375 cells assessed as reduction in cell viability preincubated for 4 hrs under dark condition in presence of 5-aminolevulinic acid followed by irradiation with blue light at 2.5 J.cm^-2 energy level for 5 mins and measured aft
|
[PMID: 38626642] |
| HEK-293T | EC50 |
40 μM
Compound: DFP
|
Protection against cisplatin-induced cytotoxicity in HEK293T cells assessed as cell viability measured after 24 to 48 hrs by MTT assay
Protection against cisplatin-induced cytotoxicity in HEK293T cells assessed as cell viability measured after 24 to 48 hrs by MTT assay
|
[PMID: 37976709] |
| HeLa | IC50 |
61.84 μM
Compound: DFP
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability preincubated for 4 hrs under dark condition in presence of 5-aminolevulinic acid followed by irradiation with blue light at 2.5 J.cm^-2 energy level for 5 mins and measured afte
Cytotoxicity against human HeLa cells assessed as reduction in cell viability preincubated for 4 hrs under dark condition in presence of 5-aminolevulinic acid followed by irradiation with blue light at 2.5 J.cm^-2 energy level for 5 mins and measured afte
|
[PMID: 38626642] |
| HK-2 | CC50 |
>100 μM
Compound: DFP
|
Cytotoxicity against human HK-2 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Cytotoxicity against human HK-2 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 37976703] |
| HK-2 | EC50 |
>100 μM
Compound: DFP
|
Inhibition of RSL-3 induced ferroptosis in human HK-2 cells incubated for 48 hrs in presence of FAC
Inhibition of RSL-3 induced ferroptosis in human HK-2 cells incubated for 48 hrs in presence of FAC
|
[PMID: 37976703] |
| HL-60 | GI50 |
>100 μM
Compound: 1a
|
Cytotoxicity against human HL60 cells by alamar blue assay
Cytotoxicity against human HL60 cells by alamar blue assay
|
[PMID: 23266185] |
| HT-22 | EC50 |
164.6 μM
Compound: DFP
|
Anti-ferroptotic activity in erastin-induced ferroptosis in mouse HT-22 cells assessed as cell viability incubated for 24 hrs by MTT assay
Anti-ferroptotic activity in erastin-induced ferroptosis in mouse HT-22 cells assessed as cell viability incubated for 24 hrs by MTT assay
|
[PMID: 37976709] |
| L1210 | IC50 |
0.2 μM
Compound: Deferiprone
|
Antiproliferative activity against mouse L1210 cells
Antiproliferative activity against mouse L1210 cells
|
[PMID: 19601577] |
| L1210 | IC50 |
46 μM
Compound: 4 (LI)
|
Inhibitory concentration against growth of murine L1210 cells at 48 hours
Inhibitory concentration against growth of murine L1210 cells at 48 hours
|
[PMID: 15943485] |
| L1210 | IC50 |
46 μM
Compound: L1
|
Compound was tested for the growth inhibition of L1210 cell at a duration of 48 h
Compound was tested for the growth inhibition of L1210 cell at a duration of 48 h
|
[PMID: 14640556] |
| L1210 | IC50 |
55 μM
Compound: 4 (LI)
|
Inhibitory concentration against growth of murine L1210 cells at 96 hours
Inhibitory concentration against growth of murine L1210 cells at 96 hours
|
[PMID: 15943485] |
| L1210 | IC50 |
55 μM
Compound: L1
|
Compound was tested for the growth inhibition of L1210 cell at a duration of 96 h
Compound was tested for the growth inhibition of L1210 cell at a duration of 96 h
|
[PMID: 14640556] |
| MCF7 | IC50 |
64.95 μM
Compound: DFP
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability preincubated for 4 hrs under dark condition in presence of 5-aminolevulinic acid followed by irradiation with blue light at 2.5 J.cm^-2 energy level for 5 mins and measured afte
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability preincubated for 4 hrs under dark condition in presence of 5-aminolevulinic acid followed by irradiation with blue light at 2.5 J.cm^-2 energy level for 5 mins and measured afte
|
[PMID: 38626642] |
| SK-N-MC | IC50 |
165.88 μM
Compound: 2
|
Toxicity in human SK-N-MC cells by MTT method
Toxicity in human SK-N-MC cells by MTT method
|
[PMID: 20041672] |
Deferiprone (66-660 μM, 48-96 h) has a significant inhibitory effect on proliferation in TRAMP-C2, Myc-CaP, and 22rv1 cells[1].
Deferiprone (100 μM, up to 192 h) inhibits cell migration in TRAMP-C2, Myc-CaP, and 22rv1 cells[1].
Deferiprone (100 μM, 24 h) reduces the expression and activity of m-Acon in TRAMP-C2, Myc-CaP, and 22rv1 cells[1].
Deferiprone (up to 1μM, 0.5-24 h) decreases the free iron in thalassemic red blood cells[2].
Deferiprone (10 mins) inhibits human platelet aggregation stimulated by AA and ADP and epinephrine and collagen, with the IC50 values of 0.24, 0.25, 3.36 and 3.73 mM, respectively[3].
Deferiprone (0.1-3.2 μM, 5 mins) inhibits COX-1 activity with the IC50 value of 0.33 μM[3].
Deferiprone (4 mM, 5 mins) preventes ADP-induced formation of cAMP[3].
Deferiprone (156.25 μg/mL, 24 h) enhances survival rate and reduces LDH Levels and displays normal cell morphology in aged Fibroblasts[4].
Deferiprone (25μM, 6 h) amplifies the antibacterial activity of conventional antibiotics against S. epidermidis[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:TRAMP-C2, Myc-CaP, and 22rv1 cells
-
Concentration:0, 16, 30, 66, 100, 160, 300, 660 μM
-
Incubation Time:48 h, 72 h
-
Result:Showed a cytostatic effect in three cell lines with an IC50 and IC90 values of about 50 and 100 μM, respectively.
-
Cell Line:TRAMP-C2, Myc-CaP, and 22rv1 cells
-
Concentration:100 μM
-
Incubation Time:0 to 30 h for TRAMP-C2, and Myc-CaP; 0 to 192 h for 22rv1
-
Result:Inhibited cell migration starting at different time points for each cell line, ranging from 12 h in TRAMP-C2 cell to 48 h in 22rv1 cells, and 30 h in Myc-CaP cells.
-
Cell Line:TRAMP-C2, Myc-CaP, and 22rv1 cells
-
Concentration:100 μM
-
Incubation Time:24 h
-
Result:Reduced the expression of m-Acon, by 2-fold in Myc-CaP and 22 rv1 cells and decreased by 79% in TRAMP-C2 cells.
Deferiprone (50-200 mg/kg/daily for p.o., 5-10 day) reduces the nephrotoxicity in Cisplatin (HY-17394)-induced rat acute renal failure[7].
Deferiprone (13.82, 27.64 mg/kg/d for i.g., 4 weeks) exhibits anti- apoptosis and neuroprotective activity in rat Alzheimer’s disease model[8].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:The rTg(tauP301L)4510 mouse model of tauopathy[6].
-
Dosage:100 mg/kg/daily, 4 weeks
-
Administration:Intragastric administration (i.g.)
-
Result:Improved Y-maze and open field performance, and decreased 28% iron levels in brain, and reduced AT8-labeled p-tau within the hippocampus in transgenic tau mice.
-
Animal Model:Cisplatin(HY-17394)-induced rat acute renal failure model [7]
-
Dosage:50, 100, 200 mg/kg, 5-10 day
-
Administration:Oral administration
-
Result:Reduced the creatinine, BUN, malondialdehyde, iron concentrations, and the amounts of TfR, and indreased the levels of HIF-1a and related anti-apoptotic genes expression in Cisplatin (HY-17394)-injected animals.
-
Animal Model:Aluminium-linked apoptosis in rat hippocampus model (Alzheimer’s disease model) [8]
-
Dosage:13.82, 27.64 mg/kg/d, 4 week
-
Administration:Intragastric administration lasting 6 days with 1 day interval per week
-
Result:Decreased the apoptosis and the expression of Caspase-3 and Bax, and increased the expression of Bcl-2 in Aluminium-linked apoptosis in rat hippocampus.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 30652-11-0
-
Appearance Solid
-
Molecular Weight 139.15
-
Formula C7H9NO2
-
Color Off-white to light yellow
-
SMILES
O=C1C(O)=C(C)N(C)C=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (48)
-
Journal Impact Factor
-
Most Recent
-
Nat Nanotechnol
Intrinsic bioactivity of black phosphorus nanomaterials on mitotic centrosome destabilization through suppression of PLK1 kinase. [Abstract]2021 Oct;16(10):1150-1160. PMID: 34354264 -
Cell Metab
Ferroplasticity drives social isolation-induced anxiety via a ventral hippocampal iron-α-synuclein axis. [Abstract]2026 Jan 27:S1550-4131(25)00586-8. PMID: 41605214 -
Autophagy
PPP2/PP2A-mediated dephosphorylation of LC3B links PINK1-PRKN/Parkin-mediated mitophagy to SCA12 pathogenesis. [Abstract]2025 Oct 13:1-13. PMID: 41059761 -
Autophagy
2022 Apr 26:1-17. PMID: 35471096 -
Autophagy
The Paf1 complex transcriptionally regulates the mitochondrial-anchored protein Atg32 leading to activation of mitophagy. [Abstract]2020 Aug;16(8):1366-1379. PMID: 31525119
Deferiprone purchased from MedChemExpress. Usage Cited in: Autophagy. 2020 Aug;16(8):1366-1379. [Abstract]
Deferiprone (DFP) (1 mM, 24 h) treatment resulted in a moderate reduction of the levels of TIMM23 and HSPD1/HSP60, and no change of ATP5F1A by immunoblotted.
-
Adv Sci (Weinh)
2025 Aug 7:e09208. PMID: 40776529 -
J Adv Res
β-Elemene induced ferroptosis via TFEB-mediated GPX4 degradation in EGFR wide-type non-small cell lung cancer. [Abstract]2024 Aug:62:257-272. PMID: 37689240
Deferiprone purchased from MedChemExpress. Usage Cited in: J Adv Res. 2024 Aug:62:257-272. [Abstract]
A549 cells were treated with b-ELE for 24 h, CA-AM was added to cells at the final concentration of 0.5 μM, followed by adding iron chelator Deferiprone (DFP, 100 μM) for 1 h.
-
Biomaterials
A nanoformulation for immunosuppression reversal and broad-spectrum self-amplifying antitumor ferroptosis-immunotherapy. [Abstract]2023 Jan:292:121936. PMID: 36502663 -
Sci Adv
Iron deficiency-induced ferritinophagy impairs skeletal muscle regeneration through RNF20-mediated H2Bub1 modification. [Abstract]2023 Nov 15;9(46):eadf4345. PMID: 37976359 -
Redox Biol
JWA binding to NCOA4 alleviates degeneration in dopaminergic neurons through suppression of ferritinophagy in Parkinson's disease. [Abstract]2024 May 13:73:103190. PMID: 38744191 -
Redox Biol
O-GlcNAcylation regulates the stability of transferrin receptor (TFRC) to control the ferroptosis in hepatocellular carcinoma cells. [Abstract]2024 May 8:73:103182. PMID: 38744192
Deferiprone purchased from MedChemExpress. Usage Cited in: Redox Biol. 2024 May 8:73:103182. [Abstract]
Representative fluorescence images of Deferiprone (DFP) (0. 10. 50, 100 μM)-treated or untreated C2C12 cells expressing NCOA4 (green) and LC3B (red).
Deferiprone purchased from MedChemExpress. Usage Cited in: Redox Biol. 2024 May 8:73:103182. [Abstract]
mRNA levels of MyHC, MyoD and MyoG in C2C12 cells treated with 0, 10, 25, 50, 75 and 100 µM Deferiprone (DFP) in differentiation medium for 3 days.
Deferiprone purchased from MedChemExpress. Usage Cited in: Redox Biol. 2024 May 8:73:103182. [Abstract]
Immunofluorescence staining for MyHC, MyoD and MyoG in C2C12 cells treated with 0, 10, 50 and 100 µM Deferiprone (DFP) in differentiation medium for 3 days.
-
Redox Biol
Mesenchymal stem cell attenuates spinal cord injury by inhibiting mitochondrial quality control-associated neuronal ferroptosis. [Abstract]2023 Nov:67:102871. PMID: 37699320 -
Redox Biol
A catalase inhibitor: Targeting the NADPH-binding site for castration-resistant prostate cancer therapy. [Abstract]2023 Jul:63:102751. PMID: 37216701 -
Redox Biol
miR-30-5p-mediated ferroptosis of trophoblasts is implicated in the pathogenesis of preeclampsia. [Abstract]2020 Jan;29:101402. PMID: 31926626 -
J Hazard Mater
ZnO NPs delay the recovery of psoriasis-like skin lesions through promoting nuclear translocation of p-NFκB p65 and cysteine deficiency in keratinocytes. [Abstract]2021 May 15;410:124566. PMID: 33323305 -
MedComm
Repurposing iron chelators for accurate positron emission tomography imaging tracking of radiometal-labeled cell transplants. [Abstract]2024 Jan 30;5(2):e473. PMID: 38292327 -
Mol Biomed
Iron accumulation in hypothalamus promotes age-dependent obesity and metabolic dysfunction of male mice. [Abstract]2025 Oct 2;6(1):75. PMID: 41037185 -
Food Chem
Fish oil nano-emulsion kills macrophage: Ferroptosis triggered by catalase-catalysed superoxide eruption. [Abstract]2023 May 15:408:135249. PMID: 36566546 -
Environ Int
Gestational exposure to nanoplastics disrupts fetal development by promoting the placental aging via ferroptosis of syncytiotrophoblast. [Abstract]2025 Mar:197:109361. PMID: 40080956 -
J Colloid Interface Sci
Orchestrating apoptosis and ferroptosis through enhanced sonodynamic therapy using amorphous UIO-66-CoOx. [Abstract]2024 Aug:667:91-100. PMID: 38621335 -
Acta Biomater
Iron ion and sulfasalazine-loaded polydopamine nanoparticles for Fenton reaction and glutathione peroxidase 4 inactivation for enhanced cancer ferrotherapy. [Abstract]2022 Jun;145:210-221. PMID: 35470077 -
-
Cell Commun Signal
Uncovering the role of ferroptosis in Bietti crystalline dystrophy and potential therapeutic strategies. [Abstract]2024 Jul 11;22(1):359. PMID: 38992691 -
Phytomedicine
Ginkgetin derived from Ginkgo biloba leaves enhances the therapeutic effect of cisplatin via ferroptosis-mediated disruption of the Nrf2/HO-1 axis in EGFR wild-type non-small-cell lung cancer. [Abstract]2021 Jan;80:153370. PMID: 33113504 -
Free Radic Biol Med
GLS1-mediated glutamine metabolism mitigates oxidative stress-induced matrix degradation, ferroptosis, and senescence in nucleus pulposus cells by modulating Fe2+ homeostasis. [Abstract]2025 Feb 16:228:93-107. PMID: 39710108 -
Free Radic Biol Med
Cryptochrome 1 regulates ovarian granulosa cell senescence through NCOA4-mediated ferritinophagy. [Abstract]2024 May 1:217:1-14. PMID: 38522484 -
Free Radic Biol Med
2020 Nov 20;160:303-318. PMID: 32846217 -
Chemosphere
2021 Feb;264(Pt 1):128413. PMID: 33017703 -
Sci Total Environ
Ferritinophagy activation and sideroflexin1-dependent mitochondrial iron overload contribute to patulin-induced cardiac inflammation and fibrosis. [Abstract]2023 Sep 20:892:164472. PMID: 37257617 -
Sci Total Environ
Chronic arsenic exposure induces ferroptosis via enhancing ferritinophagy in chicken livers. [Abstract]2023 Sep 10:890:164172. PMID: 37201840 -
Biomed Pharmacother
Puerarin protects against iron overload-induced retinal injury through regulation of iron-handling proteins. [Abstract]2020 Feb;122:109690. PMID: 31786468 -
Cell Rep
A mitochondrial inside-out iron-calcium signal reveals drug targets for Parkinson's disease. [Abstract]2023 Dec 6;42(12):113544. PMID: 38060381 -
Cell Biosci
2026 Apr 26. PMID: 42036719 -
EMBO Rep
2019 Jul;20(7):e47563. PMID: 31267712 -
Int J Mol Med
Curcumin pretreatment attenuates myocardial ischemia/reperfusion injury by inhibiting ferroptosis, autophagy and apoptosis via HES1. [Abstract]2024 Dec;54(6):110. PMID: 39364745 -
Chin Med
Quercetagetin alleviates liver fibrosis in non-alcoholic fatty liver disease by promoting ferroptosis of hepatic stellate cells through GPX4 ubiquitination. [Abstract]2025 Jun 16;20(1):89. PMID: 40524220 -
Biochem Pharmacol
Chrysin induces autophagy-dependent ferroptosis to increase chemosensitivity to gemcitabine by targeting CBR1 in pancreatic cancer cells. [Abstract]2021 Nov:193:114813. PMID: 34673014 -
Mol Cell Proteomics
Proteomics, Transcriptomics, and Phosphoproteomics Reveal the Mechanism of Talaroconvolutin-A Suppressing Bladder Cancer via Blocking Cell Cycle and Triggering Ferroptosis. [Abstract]2023 Dec;22(12):100672. PMID: 37866481 -
Eur J Pharmacol
Hinokitiol protects gastric injury from ethanol exposure via its iron sequestration capacity. [Abstract]2024 Mar 5:966:176340. PMID: 38244759 -
Mol Med Rep
Co‑treatment with triptolide and RSL3 induces hepatocellular carcinoma cell apoptosis and ferroptosis. [Abstract]2025 Jul;32(1):202. PMID: 40376993 -
PLoS Negl Trop Dis
Iron-overload-induced ferroptosis in mouse cerebral toxoplasmosis promotes brain injury and could be inhibited by Deferiprone. [Abstract]2023 Aug 31;17(8):e0011607. PMID: 37651502 -
Toxicol Appl Pharmacol
Fostered Nrf2 expression antagonizes iron overload and glutathione depletion to promote resistance of neuron-like cells to ferroptosis. [Abstract]2020 Nov 15;407:115241. PMID: 32937103 -
Metallomics
2024 Oct 4;16(10):mfae044. PMID: 39317669 -
Mitochondrial Commun
2024:2:14-20. PMID: 38347884 -
-
Oxid Med Cell Longev
HO-1 Contributes to Luteolin-Triggered Ferroptosis in Clear Cell Renal Cell Carcinoma via Increasing the Labile Iron Pool and Promoting Lipid Peroxidation. [Abstract]2022 Apr 25;2022:3846217. PMID: 35656025 -
-
Solvent & Solubility
DMSO : 7.14 mg/mL (51.31 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 3.33 mg/mL (23.93 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 0.71 mg/mL (5.10 mM); Clear solution
This protocol yields a clear solution of ≥ 0.71 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (7.1 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 0.71 mg/mL (5.10 mM); Clear solution
This protocol yields a clear solution of ≥ 0.71 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (7.1 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 10 mg/mL (71.86 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (319 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Portuguese - PT (392 KB)
-
Handling Instructions (2659 KB)
References
[1]. Rui V. Simões, Inhibition of prostate cancer proliferation by Deferiprone. NMR Biomed [Content Brief]
[2]. Oded Shalev. et al. Deferiprone (L1) Chelates Pathologic Iron Deposits From Membranes of Intact Thalassemic and Sickle Red Blood Cells Both In Vitro and In Vivo. [Content Brief]
[3]. Ngan Thi Tran, et al. Antiplatelet activity of deferiprone through cyclooxygenase-1 inhibition. Platelets 2020 May 18;31(4):505-512. [Content Brief]
[4]. Andrea Pagani, MD, et al. Deferiprone Stimulates Aged Dermal Fibroblasts via HIF-1α Modulation.Pathog Dis. 2018 Jul 1;76(5). [Content Brief]
[5]. Débora C Coraça-Huber, et al. Iron chelation destabilizes bacterial biofilms and potentiates the antimicrobial activity of antibiotics against coagulase-negative Staphylococci. Pathogens and Disease, Volume 76, Issue 5, July 2018, fty052 [Content Brief]
[6]. Shalini S. Rao, et al. Deferiprone Treatment in Aged Transgenic Tau Mice Improves Y-Maze Performance and Alters Tau Pathology. Neurotherapeutics. 2021 Apr;18(2):1081-1094. [Content Brief]
[7]. Makhdoumi P, et al. Oral deferiprone administration ameliorates cisplatin-induced nephrotoxicity in rats.J Pharm Pharmacol. 2018 Oct;70(10):1357-1368. [Content Brief]
[8]. Johnston A, et al. Transcriptomic Signature and PROTAC Strategy Revealed Histone Lysine Demethylase as a Target of Anticancer Activity of Deferiprone. ACS Omega. 2026;11(18):26421-26437. [Content Brief]
[9]. Kontoghiorghes GJ, et al. Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine. Drug Saf. 2003;26(8):553-584. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 7.1865 mL | 35.9324 mL | 71.8649 mL | 179.6622 mL |
| 5 mM | 1.4373 mL | 7.1865 mL | 14.3730 mL | 35.9324 mL | |
| 10 mM | 0.7186 mL | 3.5932 mL | 7.1865 mL | 17.9662 mL | |
| 15 mM | 0.4791 mL | 2.3955 mL | 4.7910 mL | 11.9775 mL | |
| 20 mM | 0.3593 mL | 1.7966 mL | 3.5932 mL | 8.9831 mL | |
| DMSO | 25 mM | 0.2875 mL | 1.4373 mL | 2.8746 mL | 7.1865 mL |
| 30 mM | 0.2395 mL | 1.1977 mL | 2.3955 mL | 5.9887 mL | |
| 40 mM | 0.1797 mL | 0.8983 mL | 1.7966 mL | 4.4916 mL | |
| 50 mM | 0.1437 mL | 0.7186 mL | 1.4373 mL | 3.5932 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Powered by Bioz